close
close

Elevance Health, Inc. (NYSE:ELV) Shares Sold by AEGON ASSET MANAGEMENT UK Plc

Elevance Health, Inc. (NYSE:ELV) Shares Sold by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc trimmed its holdings in Elevance Health, Inc. (NYSE:ELV – Get Rating) by 1.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,292 shares of the company’s stock after selling 427 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc’s holdings in Elevance Health were worth $17,138,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Crewe Advisors LLC acquired a new position in Elevance Health in the fourth quarter worth approximately $25,000. Moisand Fitzgerald Tamayo LLC purchased a new position in Elevance Health in the 4th quarter worth about $25,000. Hexagon Capital Partners LLC purchased a new stake in Elevance Health during the fourth quarter valued at about $26,000. Destiny Wealth Partners LLC purchased a new position in shares of Elevance Health in the fourth quarter worth approximately $26,000. Finally, Sugarloaf Wealth Management LLC purchased a new position in shares of Elevance Health during the fourth quarter valued at $26,000. Institutional investors own 88.30% of the company’s stock.

Elevance Health Price Performance

NYSE:ELV traded up $1.20 during trading hours on Friday, reaching $451.07. The company had a trading volume of 385,821 shares, compared to its average volume of 1,183,005. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average of $458.85 and a two-hundred day moving average of $476.64. Elevance Health, Inc. has a one year low of $428.87 and a one year high of $549.52. The firm has a market capitalization of $106.93 billion, a PE ratio of 17.51, a PEG ratio of 1.12 and a beta of 0.85.

See also  Dover Co. (NYSE:DOV) Shares Sold by Wells Fargo & Company MN

Elevance Health (NYSE:ELV – Get Rating) last posted its earnings results on Wednesday, April 19th. The company reported $9.46 earnings per share for the quarter, topping the consensus estimate of $9.26 by $0.20. The business had revenue of $41.90 billion for the quarter, compared to analyst estimates of $40.93 billion. Elevance Health had a net margin of 3.86% and a return on equity of 20.05%. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $8.25 EPS. Analysts forecast that Elevance Health, Inc. will post 32.78 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 23rd. Shareholders of record on Friday, June 9th will be paid a $1.48 dividend. This represents a $5.92 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date is Thursday, June 8th. Elevance Health’s dividend payout ratio is currently 23.04%.

Analysts Set New Price Targets

ELV has been the subject of several research reports. TD Cowen decreased their price target on shares of Elevance Health from $577.00 to $564.00 and set an “outperform” rating for the company in a report on Thursday, April 20th. Morgan Stanley upgraded shares of Elevance Health from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $500.00 to $571.00 in a report on Thursday, April 27th. JPMorgan Chase & Co. upped their price target on shares of Elevance Health from $555.00 to $572.00 and gave the stock an “overweight” rating in a research note on Thursday, February 23rd. Royal Bank of Canada upgraded Elevance Health from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $523.00 to $572.00 in a research note on Tuesday, March 28th. Finally, Wells Fargo & Company dropped their price objective on Elevance Health from $597.00 to $561.00 in a report on Monday, April 24th. One equities research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $569.27.

See also  “How Seeing Wizkid in 2018 Made Know I Was Going to Make It”: Joeboy Reveals Defining Moment in His Career

About Elevance Health

(Get Rating)

Elevance Health, Inc operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance.

Recommended Stories

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Elevance Health, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Elevance Health wasn’t on the list.

While Elevance Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

  • June 24, 2023